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Abstract
Background: Neuronal transduction by adeno-associated viral (AAV) vectors has been demonstrated in cortex, 
brainstem, cerebellum, and sensory ganglia. Intrathecal delivery of AAV serotypes that transduce neurons in dorsal root 
ganglia (DRG) and spinal cord offers substantial opportunities to 1) further study mechanisms underlying chronic pain, 
and 2) develop novel gene-based therapies for the treatment and management of chronic pain using a non-invasive 
delivery route with established safety margins. In this study we have compared expression patterns of AAV serotype 5 
(AAV5)- and AAV serotype 8 (AAV8)-mediated gene transfer to sensory neurons following intrathecal delivery by direct 
lumbar puncture.
Results: Intravenous mannitol pre-treatment significantly enhanced transduction of primary sensory neurons after 
direct lumbar puncture injection of AAV5 (rAAV5-GFP) or AAV8 (rAAV8-GFP) carrying the green fluorescent protein 
(GFP) gene. The presence of GFP in DRG neurons was consistent with the following evidence for primary afferent origin 
of the majority of GFP-positive fibers in spinal cord: 1) GFP-positive axons were evident in both dorsal roots and dorsal 
columns; and 2) dorsal rhizotomy, which severs the primary afferent input to spinal cord, abolished the majority of GFP 
labeling in dorsal horn. We found that both rAAV5-GFP and rAAV8-GFP appear to preferentially target large-diameter 
DRG neurons, while excluding the isolectin-B4 (IB4) -binding population of small diameter neurons. In addition, a larger 
proportion of CGRP-positive cells was transduced by rAAV5-GFP, compared to rAAV8-GFP.
Conclusions: The present study demonstrates the feasibility of minimally invasive gene transfer to sensory neurons 
using direct lumbar puncture and provides evidence for differential targeting of subtypes of DRG neurons by AAV 
vectors.
Introduction
Pain signals originate at the peripheral terminals of sen-
sory neurons and via their central processes are transmit-
ted to second order neurons in the dorsal horn of spinal
cord. Gene therapy targeted to the spinal cord or sensory
neurons could, after a single administration, provide
long-term pain relief with reduced adverse effects relative
to current standards of practice in chronic pain manage-
ment. Additionally, gene transfer directed to specific neu-
ronal subtypes within dorsal root ganglia (DRG) could
greatly empower ongoing basic research focused upon
delineating functional differences between distinct noci-
ceptive neuronal populations. With respect to the panel
of viral vectors available for gene transfer, AAV has the
advantage of conferring stable, long-term gene expres-
sion in the absence of an inflammatory response [1]. Fur-
ther, AAV vectors are able to transduce non-dividing cells
(such as neurons), and can accommodate gene expression
cassettes of up to 4.3 kB, which is well within the range of
many genes potentially useful for pain control [2]. AAV
serotype 2 (AAV2) has been the most widely studied
serotype. However, recent studies of AAV serotypes 5 and
8 (AAV5 and AAV8) have demonstrated significantly
increased gene transfer efficiency, and wider distribution
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AAV2 [3,4]. In addition, self-complementary AAV8-
mediated transduction of DRG neurons has been recently
reported [5].
Viral vector-mediated gene transfer to DRG neurons,
spinal cord neurons, glia, and pia mater has been
achieved in animal models using direct tissue injection
methods (intraparenchymal or intraneural) [2,6,7] or
intrathecal (i.t.) injection through an atlanto-occipital
catheter [5,8-10]. The primary limitations of these deliv-
ery approaches include requisite surgery and potential for
inflammation and tissue damage [11-16]. Acute intrathe-
cal (i.t.) delivery, which is applied clinically as well as for
basic neuropharmacological research [17], offers a rela-
tively non-invasive route of administration for viral vec-
tor-mediated gene transfer. However, viral vector
administration by direct lumbar puncture has not previ-
ously been reported to result in appreciable transduction
of spinal cord and DRG neurons [2]. In the present study,
we evaluated intravenous mannitol pretreatment as a
strategy for increasing the access of viral particles deliv-
ered i.t. via direct lumbar puncture to spinal cord paren-
chyma and DRG. Mannitol is used to control intracranial
pressure [18] and to disrupt the intercellular tight junc-
tions between endothelial cells of the CNS microvascula-
ture [19]. It is also used intravenously (i.v.) to facilitate
chemotherapeutic drug delivery to the CNS [19]. In ani-
mal models, mannitol, given i.v. as a pretreatment,
enhanced intraparenchymal diffusion following intrac-
erebroventricular (i.c.v.) delivery of AAV constructs
[20,21]. Therefore, we hypothesized that i.v. pretreatment
with mannitol would similarly enhance penetration of
AAV vectors to the spinal cord parenchyma and to the
cell bodies of DRG neurons.
Entry of AAV particles into cells is mediated by binding
to a combination of cell-surface molecules acting as
receptors or co-receptors, with different serotypes bind-
ing to different combinations of surface molecules. For
example, AAV2 utilizes heparan sulfate proteoglycans as
receptors and a number of other cell-surface molecules,
such as fibroblast growth factor receptor 1 and hepato-
cyte growth factor receptor, as co-receptors [22-26]. Less
is known about the receptors and co-receptors of AAV5
and AAV8 [22,27,28]. Differential expression of cell-sur-
face molecules required for entry of AAV vectors may
lead to differential tissue tropism among AAV serotypes.
DRG neurons are heterogeneous in terms of cell soma
size, myelination level, response properties, and neuro-
chemistry, raising the possibility for differential targeting
of DRG neuronal subtypes by different AAV vectors. The
present study provides a quantitative evaluation of the
DRG neuronal subtypes expressing green fluorescent
protein (GFP) after transduction by both rAAV5-GFP
and rAAV8-GFP, based on cell soma size and labeling for
the neurochemical markers calcitonin gene-related pep-
tide (CGRP), isolectin-B4 (IB4), and substance P (SP).
Results
rAAV5-GFP or rAAV8-GFP were injected intrathecally
b y  l u m b a r  p u n c t u r e  a s  d e s c r i b e d  i n  M e t h o d s .  G F P
expression following rAAV5-GFP administration was
substantially more abundant in spinal cords from manni-
tol-pretreated compared to saline-pretreated mice (Fig.
1A and 1B). GFP was also present in DRG neurons of
mannitol-pretreated mice (Fig 1C). The number of GFP-
positive DRG neurons was significantly higher (Mann-
Whitney, U05(1),3,3 = 9, p = 0.05) in lumbar DRG of manni-
tol-pretreated mice compared to that of saline-pretreated
mice (Fig. 1C and 1D). Intravenous pretreatment with
mannitol similarly resulted in higher levels of GFP in spi-
nal cord and DRG following i.t. administration of rAAV8-
GFP (data not shown).
GFP was observed at all levels of mouse spinal cord fol-
lowing treatment with rAAV5-GFP (Fig. 2) and rAAV8-
GFP (not shown) with notable differences in the caudal-
rostral distribution. GFP was abundant in the dorsal horn
at sacral (Fig. 2A), lumbar (Fig. 2B), and cervical levels
(Fig. 2D). In contrast, labeling in thoracic spinal cord was
more limited and appeared to be restricted to the dorsal
columns and Clarke's Columns (Fig. 2C). At all levels of
spinal cord, GFP appeared to be associated predomi-
nantly with nerve fibers. However, it was generally absent
from the substantia gelatinosa (lamina II) of dorsal horn.
Labeling of a small number of spinal cord neurons was
most evident at lumbosacral levels where GFP neurons
were seen in both dorsal (not shown) and ventral horn
(Fig. 3A and 3B). In addition, double labeling with GFAP
identified a small number of GFP-positive astrocytes (Fig.
3C and 3D). Reducing the injection volume (and conse-
quently the viral load) resulted in predominantly lum-
bosacral localization of GFP-ir (data not shown).
To determine whether the GFP observed in fibers of the
dorsal horn originated from primary afferent neurons
whose cell bodies are found in DRG, dorsal rhizotomies
w e r e  p e r f o r m e d  i n  r A A V 5 - G F P  i n j e c t e d  r a t s  ( 6  w e e k s
post-injection) to sever input from the DRG. The pattern
of labeling in rat was consistent with that of mouse at all
spinal cord levels. GFP was notably reduced in the dorsal
horn ipsilateral to the severed dorsal roots in contrast to
abundant GFP labeling on the contralateral, unoperated
side (Fig. 4A and 4C). Double-labeling with antiserum
directed against substance P (SP) showed that SP-ir was
also reduced in the ipsilateral dorsal horn of rhizoto-
mized rats (Fig. 4B and 4D), confirming the disruption of
afferent input. Further evidence suggesting GFP localiza-
tion in the central processes of primary afferent neurons
was the observation of labeling in dorsal roots as well as
in the dorsal columns.Vulchanova et al. Molecular Pain 2010, 6:31
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In mouse DRG, GFP was seen in neuronal cell bodies
and fibers after both rAAV5-GFP (as shown in Fig 1C)
and rAAV8-GFP treatment (data not shown). However, in
rAAV8-GFP treated DRG, GFP labeling was also
observed in non-neuronal cells, which did not co-label
with markers of glial cells (data not shown). Quantitative
image analysis of DRG from mice injected with rAAV5-
GFP (Fig. 5A-H) or rAAV8-GFP (Fig. 5I-P) was per-
formed in DRG sections labeled with anti-CGRP and IB4
and counterstained with NeuroTrace (Fig. 5). The pro-
portions of CGRP-positive and IB4-positive neurons
determined in these experiments (AAV5: CGRP, 37.0 +/-
Figure 1 Mannitol enhances GFP expression in mouse spinal cord and DRG. Sections are from mice perfused six weeks after i.t. injection of 
rAAV5-GFP with or without intravenous mannitol pretreatment. A) GFP immunoreactivity (-ir) in the spinal cord of a mannitol-pretreated mouse. B) 
GFP-ir in spinal cord of a saline-pretreated mouse. C) GFP-ir in L4 DRG of a mannitol-pretreated mouse. D) Mannitol pretreatment significantly enhanc-
es transduction of lumbar DRG neurons when compared to saline pretreatment; Mann-Whitney, U05(1),3,3 = 9, p = 0.05.
Figure 2 GFP-ir in representative sections of mouse spinal cord. A) Sacral, B) lumbar, C) thoracic, and D) cervical spinal cord sections from mice 
perfused six weeks after i.v. mannitol pretreatment and i.t. rAAV5-GFP injection.Vulchanova et al. Molecular Pain 2010, 6:31
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1.6%, IB4, 23.4 +/- 1.7%; AAV8: CGRP, 28.6 +/- 0.5%; IB4,
24.4 +/- 2.2%) were consistent with previous reports [29-
31]. Notably, we found that approximately 30% of neu-
rons with diameter less than 22 μm were not labeled by
either anti-CGRP or IB4 (AAV5: 31.3 +/- 1.8%; AAV8:
35.6 +/- 2.9%). GFP-ir was observed predominantly in
neurons with diameter greater than 22 μm (Fig. 6A). Of
the GFP-positive neurons with diameter less than 22 μm,
a larger proportion was CGRP-positive following rAAV5-
GFP than following rAAV8-GFP treatment: t-test, t.05,2,4 =
3.421, p < 0.05 (Fig. 6B). Double labeling with anti-CGRP
and anti-SP showed that both peptides were present in a
subset of GFP-positive neurons after rAAV5-GFP treat-
ment (Fig. 7). The number of IB4/GFP-positive neurons
after both rAAV5-GFP and rAAV8-GFP was very limited
(Fig. 5H and 5P, and Fig. 6B).
Discussion
The present study demonstrates the feasibility of gene
transfer to sensory neurons using direct lumbar punc-
ture. As a delivery method to the intrathecal space, direct
lumbar puncture is both minimally invasive and mini-
mally damaging to the spinal cord parenchyma since it
does not require surgery or catheter maintenance. The
utility of gene transfer to sensory neurons for furthering
studies of pain pathways as well as potentially for pain
management at the spinal level would be increased by the
development of viral vectors that selectively target sub-
types of sensory neurons. To that end, our results provide
evidence for differential targeting of DRG neurons by
AAV vectors.
Intrathecal delivery using the atlanto-occipital cathe-
terization approach [8] has successfully achieved gene
transfer at the level of the pia mater [9], intrinsic spinal
cord neurons, and sensory neurons [5,10]. The strength
of the i.t. catheterization approach has largely been its
application for reliable continuous infusion or repeated
injections [11]. However, given that a single AAV injec-
tion is sufficient to transduce a substantive number of
neurons, optimization of a less invasive non-surgical
delivery approach in animal models is warranted. Due to
its hyperosmotic properties, mannitol compromises the
tight junctions of the blood brain barrier and conse-
Figure 3 GFP-ir in neurons and astrocytes within the ventral horn 
of mouse lumbar spinal cord. GFP-ir (green) is observed in both large 
neurons expressing NeuN-ir (red, A and B) and astrocytes expressing 
GFAP-ir (red, C and D).
Figure 4 Dorsal rhizotomy reduces GFP and SP labeling in spinal 
cord. GFP- (A and B) and substance P-ir (C and D) in rat lumbar spinal 
cord. Unilateral dorsal rhizotomy was performed 6 weeks after i.v. man-
nitol pretreatment and i.t. rAAV5-GFP injection. GFP-ir is reduced ipsi-
laterally to dorsal rhizotomy (A and B). Reduction in SP-ir in the same 
section (C and D) demonstrates the efficacy of the surgical procedure.
Figure 5 GFP expression in DRG. GFP-ir after i.v. mannitol pretreat-
ment and i.t. injection of either rAAV5-GFP (A-H), or rAAV8-GFP (I-P) in 
mouse L5 DRG. GFP-ir (green) is found in cells expressing CGRP-ir (red) 
(A-D and I-L) but not in cells that bind IB4 (red) (E-H and M-P)Vulchanova et al. Molecular Pain 2010, 6:31
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quently has been used to enhance CNS delivery of che-
motherapeutic agents [19]. Furthermore, i.v. mannitol has
been used in rodents to expand distribution of AAV vec-
tors into brain parenchyma following intracerebroven-
tricular injection [20,21]. The present study showed that
the same concentration of i.v. mannitol similarly
enhanced penetration of AAV5-GFP and AAV8-GFP vec-
tors to the spinal cord parenchyma and to the dorsal root
ganglia. Although GFP labeling in spinal cord was present
predominantly in nerve fibers, a small number of trans-
duced dorsal and ventral horn neurons as well as astro-
cytes was consistently observed, suggesting that both
viral vectors are capable of gaining access to these cells.
The distribution of GFP labeling in spinal cord and
DRG suggests that AAV5 and AAV8 target sensory neu-
rons differentially. The pattern of GFP-labeled nerve
fibers in spinal cord was consistent with the subsets of
DRG neurons identified as GFP-positive. At cervical,
lumbar and sacral level, GFP labeled fibers were seen pre-
dominantly in deeper laminae of dorsal horn and in the
dorsal columns, in agreement with the observation that
both AAV5 and AAV8 preferentially transduce larger
diameter DRG neurons. The pattern of GFP labeling in
thoracic spinal cord was notably different from other lev-
els (in both rat and mouse) and appeared restricted to the
dorsal columns and Clarke's columns. The reason for this
difference is unknown but may be related to differential
targeting of proprioceptive primary afferent neurons in
thoracic DRG. In contrast to AAV5 and AAV8, a recent
study reported that AAV6 targets predominantly small
diameter DRG neurons [10]. AAV5- or AAV8-mediated
gene transfer could be useful for manipulating protein
expression in large sensory neurons, which commonly
signal innocuous stimuli, but may also carry pain signals
in allodynic conditions [32].
GFP-labeled fibers were also present in lamina I of the
spinal cord. These fibers most likely represented collater-
als of large diameter neurons as well as terminations of
the small subset of peptidergic neurons that was targeted
by the vectors. The distribution of GFP in superficial dor-
sal horn from AAV5- and AAV8-treated mice was similar.
However, quantitative analysis in DRG indicated that
while nearly all of the rAAV5-GFP transduced neurons
with diameter less than 22 μm were also CGRP-positive,
Figure 6 Quantitative image analysis of GFP-expressing DRG neurons. A) A similar number of neurons smaller than 22 μm (≤22 μm), or larger 
than 22 μm (>22 μm) expressed GFP after both rAAV5-GFP and rAAV8-GFP injection. Both vectors preferentially targeted large neurons. B) Injection 
of rAAV5-GFP resulted in more GFP expression in CGRP-positive neurons smaller than 22 μm than was seen with injection of rAAV8-GFP; t-test, t.05,2,4 
= 3.421, p = 0.0268. Injection of either vector did not result in GFP expression in a substantial portion of the IB4-binding population. C) Approximately 
80% of the DRG neurons expressing GFP were larger than 22 μm, regardless of whether rAAV5-GFP or rAAV8-GFP was injected. Approximately 20% of 
these GFP-expressing neurons were also CGRP positive.
Figure 7 Colocalization of GFP-ir with SP- and CGRP-ir in DRG Neurons. GFP colocalization with CGRP and SP after i.t. delivery of AAV5-GFP in 
mice. A) GFP fluorescence. B) CGRP-ir. C) SP-ir. D) Merged image. Of 10 GFP-positive neurons in this image, 6 show CGRP-ir (indicated by single arrows), 
and of those 6, 1 also displays SP-ir (indicated by arrowhead).Vulchanova et al. Molecular Pain 2010, 6:31
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rAAV8-GFP transduced a significantly smaller propor-
tion of CGRP-positive neurons of this size. Since the pop-
ulation of CGRP neurons is heterogeneous, this
observation may indicate differential expression of recep-
tors for AAV5 and AAV8 within the different subsets of
CGRP-positive neurons.
It is noteworthy that GFP labeling was minimal in lam-
ina II (substantia gelatinosa, SG) at all levels of the spinal
cord. Similar observations have been made in studies of
AAV2-MOR expression following intraneural injection
[6] and AAV8-GFP following i.t. injection by the atlanto-
occipital catheterization method [5]. The reason for
absence of GFP-ir in the SG is unclear. It is likely that, in
our experiments, the low levels of GFP in SG are due to
the limited targeting of neurons smaller than 22 μm, in
particular the minimal transduction of IB4-binding neu-
rons. Interestingly, AAV6-GFP delivery to the intrathecal
space via the atlanto-occipital approach resulted in sub-
stantial transduction of IB4-positive neurons and in GFP
labeling in the SG of the spinal cord [10].
The observation that neither AAV5 nor AAV8 trans-
duced an appreciable number of IB4-positive neurons
suggests that these neurons lack a surface molecule
required for the entry of these vectors. While AAV5 and
AAV8 may have limited application for transduction of
mouse IB4-positive neurons, this limitation can be
advantageous for studies targeting IB4-negative neuronal
populations. In addition, the targeting of rat IB4-positive
neurons in by AA V5 and AA V8 may be different from
that of mouse, since there are notable species differences
in the neurochemical subsets of DRG neurons [31]. The
finding by Towne and colleagues [10] that AAV6 is able to
transduce mouse IB4-positive neurons indicates that
AAV6 is able to enter cells via different cell-surface mole-
cules than AAV5 and AAV8, and further supports differ-
ential targeting selectivity of neuronal subpopulations by
different AAV vectors. This evidence highlights the
importance of quantitative analysis of colocalization with
histochemical markers of neuronal sub-populations for
accurate evaluation of the tropism of various AAV vec-
tors.
Conclusion
Although several groups have tried with varied success to
use AAV vectors to transduce cells of the DRG or spinal
cord following intraparenchymal delivery, intraneural
injection, or various i.t. delivery approaches [2], none has
r e p o r t e d  a b u n d a n t  t r a n s d u c t i o n  o f  t h e  D R G  o r  o f  t h e
deeper laminae of the dorsal horn without a delivery
method requiring surgical intervention. We have demon-
strated widespread expression of GFP in the spinal cord
and select subsets of DRG neurons following i.t. adminis-
tration of rAAV5-GFP or rAAV8-GFP via direct lumbar
puncture in conscious animals pretreated with i.v. manni-
tol. The distinct patterns of transduction observed with
AAV5 and AAV8 in the present study and with AAV6 in
the study by Towne and colleagues [10] indicate that dif-
ferential targeting of DRG sub-populations by various
AAV vectors should be further investigated with the goal
of capitalizing upon such differences for both research
and therapeutic practices. Differential AAV-mediated
gene transfer to spinal cord and DRG neurons may pres-
ent multiple opportunities for genetic manipulation of
proteins that drive the processes involved in pain sensa-
tion or inhibitory control of pain.
Methods
AAV Vector and Packaging
AAV vector TRUF11, containing a CAGS-regulated GFP
sequence, has been previously described [1]. Packaging
using AAV5 or AAV8 serotype capsid was carried out at
the University of Florida Vector Core Lab of the Gene
Therapy Center (Gainesville, Florida) as previously
described [1].
Animal procedures
Experimental subjects were 20 to 25 g adult male C57BL/
6 mice (Harlan, Madison, WI). In one set of experiments,
Sprague Dawley rats (male and female), were included as
the subjects for Fig. 4 because their size renders them
more appropriate for dorsal rhizotomy experiments. All
experiments were reviewed and approved by the Institu-
tional Animal Care and Use Committee (IACUC) of the
University of Minnesota.
Injections
Subjects were injected via the tail vein with 25% mannitol
solution (200 μL) twenty minutes prior to i.t. injection of
the viral constructs. AAV constructs were delivered
in t ra t heca l ly by di r ect  lu m bar  p unct ur e  in a wak e  m ic e
[17,33] or rats [34] by an experimenter (KFK) with exten-
sive experience in this method of drug delivery. A minor
modification of the protocol was required to conserve
AAV vector. The needle (a 30-gauge, 0.5-inch (mouse) or
1.5 inch (rat)) was connected to a length of PE10 tubing,
which was then connected to a second needle that was
attached to a 50-μl Luer-hub Hamilton syringe. For both
rAAV5-GFP and rAAV8-GFP, 10 μL of the construct con-
taining 1011 viral vector genomes were injected i.t. The
injection was administered by gripping gently the iliac
crest of the rodent and inserting the needle (bevel side
up) at about a 45° angle centered approximately between
the hipbones. A reflexive flick of the tail indicated punc-
ture of the dura. Following the injection, the animals were
returned to the vivarium where they remained for six
weeks, until the time of transcardial perfusion, fixation,
and extraction of fixed spinal cord and DRG for immuno-
histochemical analysis.Vulchanova et al. Molecular Pain 2010, 6:31
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Dorsal Rhizotomy
In rats, i.v. mannitol pretreatment and i.t. rAAV5-GFP
injection was followed 6 weeks later by unilateral dorsal
rhizotomy. The rats were approximately 75 g at time of
the injections and approximately 150-175 g at time of rhi-
zhotomy and perfusion. Rats were anaesthetized with 75
mg/ml ketamine, 5 mg/kg xylazine and 1 mg/kg acepro-
mazine injected intramuscularly. After deep, surgical
anesthesia had been attained, an incision was made
through the skin overlying T10-L7 of the spinal cord. The
dorsal roots were exposed and severed close to the spinal
column. The incision was closed with surgical staples and
the animals allowed to survive for 5 days before perfusion
fixation.
Immunohistochemistry
All animals were sacrificed by perfusion fixation as previ-
ously described [35]. Briefly, animals were anaesthetized
with 100 mg/kg ketamine, 5 mg/kg xylazine, and 1 mg/kg
acepromazine injected i.m. and perfused with a solution
of calcium-free tyrodes solution (in mM:NaCl 116, KCl
5.4, MgCl2·6H20 1.6, MgSO4·7H2O 0.4, NaH2PO4 1.4, glu-
cose 5.6, and NaHCO3 26) followed by fixative (4% para-
formaldehyde and 0.2% picric acid in 0.1 M phophate
buffer, pH 6.9) followed by 10% sucrose in PBS. Spinal
cord and DRG were removed and incubated in 10%
s u c r o s e  o v e r n i g h t  a t  4 ° C .  S e c t i o n s  w e r e  c u t  a t  1 4  μ m
thickness and thaw mounted onto gel-coated slides. Tis-
sue sections were incubated for 1 hour at room tempera-
ture in diluent (PBS containing 0.3% Triton, 1% BSA, 1%
normal donkey serum) and then incubated overnight at
4°C in primary antisera diluted in the same diluent. In
some instances, GFP fluorescence was enhanced by
immunostaining with antisera to GFP. Primary antibodies
used were: rabbit anti-GFP, 1:500 (Invitrogen; Eugene,
OR), guinea pig anti-SP; 1:500 (Neuromics; Edina, MN),
rabbit anti-CGRP, 1:500 (Immunostar; Hudson, WI),
mouse anti-NeuN. 1:500 (Chemicon; Temecula, CA),
mouse anti-GFAP, 1:400 (Sigma; St. Louis, MO)), and/or
biotinylated isolectin-B4, 10 μg/ml (Sigma; St. Louis,
MO). After rinsing with PBS, sections were incubated
one hour at room temperature with appropriate combi-
nations of Cy2-, Cy3-, Cy5- (1:300), and AMCA- (1:400)
conjugated secondary antisera (Jackson ImmunoRe-
search, West Grove, CA). Sections were rinsed again in
PBS and coverslipped using glycerol and PBS containing
0.1% p-phenylenediamine (Sigma). DRG sections were
also incubated for 20 minutes at room temperature with
NeuroTrace® Red (Invitrogen; Eugene, OR). Images were
collected using confocal microscopy (Biorad MRC1024,
or Olympus Fluoview1000), analyzed using Image J
(NIH), and processed in Adobe Photoshop.
Cell Counting
Three sections from each DRG were selected such that
they were equally spaced and at least 70 μm apart. These
sections were labeled with anti-CGRP, biotinylated-IB4,
and NeuroTrace® Red for analysis of co-localization and
cell size. Seven non-overlapping images were taken across
these three sections and analyzed using Image J to mea-
sure cell body size and fluorescence intensity. Neurons
were identified and outlined based on their Nissl-like
NeuroTrace® labeling. Only cells with a visible nucleus
were counted. The cutoff of 22 μm for categorization of
neurons by size was chosen based on the width of the
largest peak in size histograms of DRG neurons. For
CGRP fluorescence intensity, a method adapted from that
of Fang and colleagues [36] was used. The average inten-
sity of the brightest 10% and the dimmest 10% of neurons
i n  e a c h  i m a g e  w as  m e a s u r e d  a n d  r e l a t i v e  fl u o r e s c e n c e
intensity for each cell was defined as 100[(intensity of
selected cell - average of dimmest 10%)/(average of
brightest 10% - average of dimmest 10%)]. Cells with a
relative fluorescence intensity of 28% or greater were con-
sidered positive, and this number consistently coincided
w i t h  c e l l s  i d e n t i f i e d  a s  p o s i t i v e  b y  v i s u a l  i n s p e c t i o n .
Because the number of GFP expressing cells in each sec-
tion was low, an alternative method was used to deter-
mine background fluorescence of GFP. The average
fluorescence of three GFP-negative cells in each image
was calculated, and GFP-positive cells were defined as
cells with average intensity greater than that of the 3 neg-
ative cells plus 3 standard deviations. IB4 positive cells
were defined using the same method as that for GFP pos-
itive cells.
Abbreviations
rAAV: recombinant adeno-associated virus; CGRP: calcitonin gene-related pep-
tide; DRG: dorsal root ganglia; GFP: green fluorescent protein; GFAP: glial fibril-
lary acidic protein; IB4: isolectin B4; i.t: intrathecal; rAAV5: rAAV serotype 5;
rAAV8: rAAV serotype 8.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
LV contributed to the experimental design and drafting of the manuscript. In
addition, she participated in all perfusions, dissections, histochemical analyses,
and imaging as well as in interpretation of results and generation of figures.
She is primarily responsible for the assurance of quality of the data and the
main conclusions.
DS assisted in perfusions and dissections and performed immunohistochemis-
try, cell quantification and imaging. He assisted in the preparation of the fig-
ures, contributed to the analysis and interpretation of the data, and edited the
manuscript.
LB initiated the studies and contributed to the experimental design and edited
the manuscript.
MR performed all perfusions and dissections and participated in histochemical
analyses and interpretation of results. She along with LV is primarily responsible
for the assurance of quality of the data and the main conclusions and edited
the manuscipt.
KPP performed the IV injections.
KFK conducted all intrathecal injections of vector and is responsible for the
quality assurance of this key technique.Vulchanova et al. Molecular Pain 2010, 6:31
http://www.molecularpain.com/content/6/1/31
Page 8 of 9
GLW participated in the experimental design and edited the manuscript.
RSM initiated the study with GLW and CF as collaborators and edited the man-
uscript.
CF organized the team, contributed to the experimental design, drafted and
edited the manuscript and supported the studies.
All authors read and approved the final manuscript.
Acknowledgements
The authors would like to thank Galina Kalyuzhnaya for her technical assis-
tance. This work was supported by the National Institute on Drug Abuse (DA-
025164 to C.A.F.) and the University of Minnesota Academic Health Center. An 
individual NRSA from NINDS (F31NS063634) and a 3 M Fellowship supports 
D.J.S. A K01 award from NIDA (K01DA017236) supported LV.
Author Details
1Departments of Veterinary and Biomedical Sciences, University of Minnesota, 
Commonwealth Avenue, Saint Paul, MN 55108, USA, 2Departments of 
Neuroscience, University of Minnesota, Church Street, Minneapolis, MN 55455, 
USA, 3Departments of Genetics Cell Biology and Development, University of 
Minnesota, Church Street, Minneapolis, MN 55455, USA, 4Departments of 
Pharmaceutics, University of Minnesota, Harvard Street, Minneapolis, MN 
55455, USA, 5Departments of Pharmacology, University of Minnesota, Church 
Street, Minneapolis, MN 55455, USA and 6Departments of Dermatology, 
University of Minnesota, Delaware Street, Minneapolis, MN 55455, USA
References
1. Kaemmerer WF, Reddy RG, Warlick CA, Hartung SD, McIvor RS, Low WC: In 
vivo transduction of cerebellar Purkinje cells using adeno-associated 
virus vectors.  Mol Ther 2000, 2:446-457.
2. Beutler AS, Banck MS, Walsh CE, Milligan ED: Intrathecal gene transfer by 
adeno-associated virus for pain.  Curr Opin Mol Ther 2005, 7:431-439.
3. Lin D, Fantz CR, Levy B, Rafi MA, Vogler C, Wenger DA, Sands MS: AAV2/5 
vector expressing galactocerebrosidase ameliorates CNS disease in the 
murine model of globoid-cell leukodystrophy more efficiently than 
AAV2.  Mol Ther 2005, 12:422-430.
4. Broekman ML, Comer LA, Hyman BT, Sena-Esteves M: Adeno-associated 
virus vectors serotyped with AAV8 capsid are more efficient than AAV-
1 or -2 serotypes for widespread gene delivery to the neonatal mouse 
brain.  Neuroscience 2006, 138:501-510.
5. Storek B, Reinhardt M, Wang C, Janssen WG, Harder NM, Banck MS, 
Morrison JH, Beutler AS: Sensory neuron targeting by self-
complementary AAV8 via lumbar puncture for chronic pain.  Proc Natl 
Acad Sci USA 2008, 105:1055-1060.
6. Xu Y, Gu Y, Xu GY, Wu P, Li GW, Huang LY: Adeno-associated viral transfer 
of opioid receptor gene to primary sensory neurons: a strategy to 
increase opioid antinociception.  Proc Natl Acad Sci USA 2003, 
100:6204-6209.
7. Finegold AA, Perez FM, Iadarola MJ: In vivo control of NMDA receptor 
transcript level in motoneurons by viral transduction of a short 
antisense gene.  Brain Res Mol Brain Res 2001, 90:17-25.
8. Yaksh TL, Jessell TM, Gamse R, Mudge AW, Leeman SE: Intrathecal 
morphine inhibits substance P release from mammalian spinal cord in 
vivo.  Nature 1980, 286:155-157.
9. Finegold AA, Mannes AJ, Iadarola MJ: A paracrine paradigm for in vivo 
gene therapy in the central nervous system: treatment of chronic pain.  
Hum Gene Ther 1999, 10:1251-1257.
10. Towne C, Pertin M, Beggah AT, Aebischer P, Decosterd I: Recombinant 
adeno-associated virus serotype 6 (rAAV2/6)-mediated gene transfer 
to nociceptive neurons through different routes of delivery.  Mol Pain 
2009, 5:52.
11. Pogatzki EM, Zahn PK, Brennan TJ: Lumbar catheterization of the 
subarachnoid space with a 32-gauge polyurethane catheter in the rat.  
Eur J Pain 2000, 4:111-113.
12. Xu JJ, Walla BC, Diaz MF, Fuller GN, Gutstein HB: Intermittent lumbar 
puncture in rats: a novel method for the experimental study of opioid 
tolerance.  Anesth Analg 2006, 103:714-720.
13. Storkson RV, Kjorsvik A, Tjolsen A, Hole K: Lumbar catheterization of the 
spinal subarachnoid space in the rat.  Journal of Neuroscience Methods 
1996, 65:167-172.
14. Sakura S, Hashimoto K, Bollen AW, Ciriales R, Drasner K: Intrathecal 
catheterization in the rat. Improved technique for morphologic 
analysis of drug-induced injury.  Anesthesiology 1996, 85:1184-1189.
15. Jones LL, Tuszynski MH: Chronic intrathecal infusions after spinal cord 
injury cause scarring and compression.  Microsc Res Tech 2001, 
54:317-324.
16. Tsang BK, He Z, Ma T, Ho IK, Eichhorn JH: Decreased paralysis and better 
motor coordination with microspinal versus PE10 intrathecal catheters 
in pain study rats.  Anesth Analg 1997, 84:591-594.
17. Fairbanks CA: Spinal delivery of analgesics in experimental models of 
pain and analgesia.  Adv Drug Deliv Rev 2003, 55:1007-1041.
18. Levin AB, Duff TA, Javid MJ: Treatment of increased intracranial pressure: 
a comparison of different hyperosmotic agents and the use of 
thiopental.  Neurosurgery 1979, 5:570-575.
19. Kroll RA, Neuwelt EA: Outwitting the blood-brain barrier for therapeutic 
purposes: osmotic opening and other means.  Neurosurgery 1998, 
42:1083-1099. discussion 1099-1100
20. Fu H, Muenzer J, Samulski RJ, Breese G, Sifford J, Zeng X, McCarty DM: Self-
complementary adeno-associated virus serotype 2 vector: global 
distribution and broad dispersion of AAV-mediated transgene 
expression in mouse brain.  Mol Ther 2003, 8:911-917.
21. Mastakov MY, Baer K, Symes CW, Leichtlein CB, Kotin RM, During MJ: 
Immunological aspects of recombinant adeno-associated virus 
delivery to the mammalian brain.  J Virol 2002, 76:8446-8454.
22. Akache B, Grimm D, Pandey K, Yant SR, Xu H, Kay MA: The 37/67-
kilodalton laminin receptor is a receptor for adeno-associated virus 
serotypes 8, 2, 3, and 9.  J Virol 2006, 80:9831-9836.
23. Asokan A, Hamra JB, Govindasamy L, Agbandje-McKenna M, Samulski RJ: 
Adeno-associated virus type 2 contains an integrin alpha5beta1 
binding domain essential for viral cell entry.  J Virol 2006, 80:8961-8969.
24. Kashiwakura Y, Tamayose K, Iwabuchi K, Hirai Y, Shimada T, Matsumoto K, 
Nakamura T, Watanabe M, Oshimi K, Daida H: Hepatocyte growth factor 
receptor is a coreceptor for adeno-associated virus type 2 infection.  J 
Virol 2005, 79:609-614.
25. Qing K, Mah C, Hansen J, Zhou S, Dwarki V, Srivastava A: Human 
fibroblast growth factor receptor 1 is a co-receptor for infection by 
adeno-associated virus 2.  Nat Med 1999, 5:71-77.
26. Summerford C, Samulski RJ: Membrane-associated heparan sulfate 
proteoglycan is a receptor for adeno-associated virus type 2 virions.  J 
Virol 1998, 72:1438-1445.
27. Di Pasquale G, Davidson BL, Stein CS, Martins I, Scudiero D, Monks A, 
Chiorini JA: Identification of PDGFR as a receptor for AAV-5 
transduction.  Nat Med 2003, 9:1306-1312.
28. Walters RW, Yi SM, Keshavjee S, Brown KE, Welsh MJ, Chiorini JA, Zabner J: 
Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is 
required for gene transfer.  J Biol Chem 2001, 276:20610-20616.
29. Baiou D, Santha P, Avelino A, Charrua A, Bacskai T, Matesz K, Cruz F, Nagy I: 
Neurochemical characterization of insulin receptor-expressing primary 
sensory neurons in wild-type and vanilloid type 1 transient receptor 
potential receptor knockout mice.  J Comp Neurol 2007, 503:334-347.
30. Zwick M, Davis BM, Woodbury CJ, Burkett JN, Koerber HR, Simpson JF, 
Albers KM: Glial cell line-derived neurotrophic factor is a survival factor 
for isolectin B4-positive, but not vanilloid receptor 1-positive, neurons 
in the mouse.  J Neurosci 2002, 22:4057-4065.
31. Price TJ, Flores CM: Critical evaluation of the colocalization between 
calcitonin gene-related peptide, substance P, transient receptor 
potential vanilloid subfamily type 1 immunoreactivities, and isolectin 
B4 binding in primary afferent neurons of the rat and mouse.  J Pain 
2007, 8:263-272.
32. Sun H, Ren K, Zhong CM, Ossipov MH, Malan TP, Lai J, Porreca F: Nerve 
injury-induced tactile allodynia is mediated via ascending spinal dorsal 
column projections.  Pain 2001, 90:105-111.
33. Hylden JL, Wilcox GL: Intrathecal morphine in mice: a new technique.  
Eur J Pharmacol 1980, 67:313-316.
34. Mestre C, Pelissier T, Fialip J, Wilcox G, Eschalier A: A method to perform 
direct transcutaneous intrathecal injection in rats.  J Pharmacol Toxicol 
Methods 1994, 32:197-200.
Received: 19 November 2009 Accepted: 28 May 2010 
Published: 28 May 2010
This article is available from: http://www.molecularpain.com/content/6/1/31 © 2010 Vulchanova et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Molecular Pain 2010, 6:31Vulchanova et al. Molecular Pain 2010, 6:31
http://www.molecularpain.com/content/6/1/31
Page 9 of 9
35. Vulchanova L, Riedl MS, Shuster SJ, Stone LS, Hargreaves KM, Buell G, 
Surprenant A, North RA, Elde R: P2 × 3 is expressed by DRG neurons that 
terminate in inner lamina II.  Eur J Neurosci 1998, 10:3470-3478.
36. Fang X, Djouhri L, McMullan S, Berry C, Waxman SG, Okuse K, Lawson SN: 
Intense isolectin-B4 binding in rat dorsal root ganglion neurons 
distinguishes C-fiber nociceptors with broad action potentials and 
high Nav1.9 expression.  J Neurosci 2006, 26:7281-7292.
doi: 10.1186/1744-8069-6-31
Cite this article as: Vulchanova et al., Differential adeno-associated virus 
mediated gene transfer to sensory neurons following intrathecal delivery by 
direct lumbar puncture Molecular Pain 2010, 6:31